J. Cancer Mol. 2:
57-66, 2006
[Review
Article]
Targeted Therapy
for Cancer
Han-Chung Wu,
De-Kuan Chang, and Chia-Ting Huang
Institute of Cellular and Organismic Biology, Academia Sinica,
Taipei, Taiwan
Abstract:
Cancer is one of the most common causes of death, taking nearly 7
million lives each year worldwide. New cancer targeted therapies
that make use therapeutic antibodies or small molecules have made
treatment more tumor-specific and less toxic.
Nevertheless,
there remain several
challenges to the treatment of cancer, including drug resistance,
cancer stem cells, and high tumor interstitial fluid pressure. In
many solid tumors, for example,
increased interstitial fluid pressure makes the uptake of
therapeutic agents less efficient. One of the most promising ways
of meeting such challenges is ligand-targeted
therapy that may be used to make targeting more specific and carry
higher dosages of anti-cancer drug to tumor tissue. This
article reviews and discusses recent advances in the treatment of
cancer and the challenges that remain.
(Keywords:
targeted therapy; therapeutic antibody; phage display; targeting
liposome)
¡@
Received
3/22/06; Revised 4/10/06; Accepted 4/10/06.
1Correspondences:
Dr. Han-Chung Wu, Institute of Cellular and Organismic Biology,
Academia Sinica, 128 Academia Road, Section 2, Nankang, Taipei
11529, Taiwan.
E-mail:
hcw0928@gate.sinica.edu.tw
2Abbreviations:
MoAb, monoclonal antibody; ADCC,
antibody-dependent cell-mediated cytotoxicity; CDC,
complement-dependent cytotoxicity;
NK, natural killer; NSCLC, non-small-cell lung cancer; IFP,
interstitial fluid pressure; CSC, cancer stem cell; NPC,
nasopharyngeal carcinoma. |
